Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kyverna Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$161.99M. For fiscal 2025 it was -$168.03M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$168.03M | – |
| FY2024 | Dec 31, 2024 | -$140.47M | – |
| FY2023 | Dec 31, 2023 | -$60.70M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$42.80M | – |
| Q2 FY2026 | Jun 30, 2026 | -$39.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.91M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$46.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$40.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$38.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.05M | – |
See a number that looks wrong?